This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Taking Lupus To Heart -- L.A. Doctor Honored

LOS ANGELES, June 20, 2013 /PRNewswire-USNewswire/ -- This is the first in a series of reports by SMA Global focusing on healthcare issues and the help and hope provided by healthcare professionals.

1.5 million Americans, mostly young women, suffer from Lupus.  It is the mysterious disease that cannot be discovered with any single laboratory test and has not enjoyed any breakthrough new treatment in fifty years.

With their immune systems under attack, patients suffer chronic fatigue and exhaustion, joint pains, memory problems, confusion and skin rashes. Their extreme flares of pain come without warning.

A recent study at Ohio State University's prestigious Center for Clinical and Translational Science concluded that patients with Lupus have a 20 to 50-fold higher rate of cardiac events than a person without Lupus. One researcher described the condition as "speeding up" and "magnifying" heart disease and most of what is happening is invisible to examiners.

A few weeks ago, actor Jason Alexander and singer Toni Braxton, a Lupus patient, both major supporters of Lupus LA, one of the nation's most respected Lupus-fighting foundations, joined in honoring Dr. Jay Schapira, a nationally renowned Cardiologist, Professor of Medicine and Researcher/Writer.

Determined to reduce the dangers of cardiac complications in lupus patients, Dr. Schapira has teamed with global colleagues to challenge the previously unchecked incidents of cardiac disease that compound the damage and danger of lupus itself.

The Chairman of Lupus LA, Adam Selkowitz, was uniquely qualified to lead the parade of honors for Dr. Schapira.  Selkowitz is not only a lupus survivor but an all-star success story among Dr. Schapira's patients perhaps best proven by his completing a 5 mile marathon this past year.

"One of the biggest problems facing lupus patients are the often unpredictable side effects from the medicines that can do us the most good," Selkowitz said.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs